Overview
CRBP market data
Price History
CRBP price chart
Valuation & Profitability
No Valuation Data Yet
Alpha Vantage and Twelve Data both returned no valuation metrics for CRBP. Check back after the next daily valuation refresh — this symbol may be new, delisted, or temporarily unavailable from both providers.
Company news
8-K filing — Corbus Pharmaceuticals Holdings, Inc. (CRBP)SEC EDGAR · Jul 6, 2026, 12:15 PM
Mizuho Maintains Outperform on Corbus Pharmaceuticals, Lowers Price Target to $34Benzinga · Jun 23, 2026, 3:10 PM
Oppenheimer Maintains Outperform on Corbus Pharmaceuticals, Lowers Price Target to $52Benzinga · Jun 17, 2026, 1:35 PM
Wedbush Maintains Outperform on Corbus Pharmaceuticals, Lowers Price Target to $30Benzinga · May 27, 2026, 1:35 PM
HC Wainwright & Co. Reiterates Buy on Corbus Pharmaceuticals, Maintains $40 Price TargetBenzinga · May 26, 2026, 4:29 PM
Corbus Pharma Reports Updated Data From Phase 1/2 Clinical Study Of CRB-701, Next-Gen Nectin-4 Targeted Antibody Drug ConjugateBenzinga · May 26, 2026, 11:05 AM
Mizuho Maintains Outperform on Corbus Pharmaceuticals, Raises Price Target to $44Benzinga · May 22, 2026, 12:05 PM
Corbus Pharmaceuticals To Discuss Updated Data For Its Phase 1/2 Trial Of CRB-701 Antibody Drug Candidate To Treat Head And Neck Squamous Cell CarcinomaBenzinga · May 21, 2026, 12:15 PM
Jefferies Maintains Buy on Corbus Pharmaceuticals, Lowers Price Target to $33Benzinga · May 13, 2026, 7:49 PM
Oppenheimer Maintains Outperform on Corbus Pharmaceuticals, Lowers Price Target to $54Benzinga · May 13, 2026, 5:08 PM